Oncopeptides announced today that it completed patient enrollment for its Phase 2 Port study of its multiple myeloma treatment. Waltham, Mass.-based Oncopeptides' Port study is an open-label, randomized, crossover study comparing the safety, … [Read More...] about Oncopeptides completes enrollment in Phase 2 multiple myeloma study
Main Content
Sponsored Content
Noble expands its services for its clients into Human Factors
Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug therapies By Tim McLeroy, Executive Director of Marketing … [Read More...] about Noble expands its services for its clients into Human Factors
Featured Posts
Ocular Therapeutix misses The Street on bottom-line leap
Ocular Therapeutix (NSDQ:OCUL) reported first-quarter results that missed the consensus forecast on Wall Street. The Bedford, Mass.–based eye disease therapeutic developer yesterday posted profits of $3.12 million, or $0.04 per share, on sales of … [Read More...] about Ocular Therapeutix misses The Street on bottom-line leap
BD to spin off its diabetes business, Q2 earnings beat The Street
BD (NYSE: BDX) announced today that it will spin off its Diabetes Care business as an independent, publicly traded company during the first half of 2022. The Diabetes Care business saw $1.1 billion in sales during BD's fiscal year ended Sept. 30, … [Read More...] about BD to spin off its diabetes business, Q2 earnings beat The Street
Lilly partners with four companies on insulin pen tech
Eli Lilly (NYSE:LLY) today announced deals with four companies whose diabetes management tech will work with on Lilly's latest insulin pen. The Tempo Pen is a modified version of Lilly's existing prefilled, disposable insulin pen to which the … [Read More...] about Lilly partners with four companies on insulin pen tech
Tandem Diabetes Care rises after hours on Street-beating Q1, raised guidance
Tandem Diabetes Care (NSDQ:TNDM) shares rose after hours today on first-quarter results that beat the consensus forecast. The San Diego-based company posted losses of -$5 million, or -8¢ per share, on sales of $141 million for the three months … [Read More...] about Tandem Diabetes Care rises after hours on Street-beating Q1, raised guidance
Oncopeptides completes enrollment in Phase 2 multiple myeloma study
Oncopeptides announced today that it completed patient enrollment for its Phase 2 Port study of its multiple myeloma treatment. Waltham, Mass.-based Oncopeptides' Port study is an open-label, randomized, crossover study comparing the safety, … [Read More...] about Oncopeptides completes enrollment in Phase 2 multiple myeloma study
United Therapeutics posts Street-beating Q1
United Therapeutics (NSDQ:UTHR) today announced first-quarter results that came in well ahead of the consensus forecast. The Research Triangle Park, N.C.-based company posted profits of $28.3 million, or 61¢ per share, on sales of $379.1 million … [Read More...] about United Therapeutics posts Street-beating Q1
Kala Pharmaceuticals rises before hours on mixed bag Q1
Kala Pharmaceuticals (NSDQ:KALA) announced shares ticked up before hours today on first-quarter results that were mixed compared to the consensus forecast. The Watertown, Mass.-based company posted losses of -$30.4 million, or -49¢ per share, on … [Read More...] about Kala Pharmaceuticals rises before hours on mixed bag Q1
Teva Pharmaceuticals launches generic Erythromycin tablets in U.S.
Teva Pharmaceuticals (NYSE:TEVA) announced today that it launched generic Erythromycin oral tablets in the U.S. Parsippany, N.J.-based Teva — a U.S. affiliate of Tel Aviv, Israel-based Teva Pharmaceutical Industries — launched the 250 mg- and 500 … [Read More...] about Teva Pharmaceuticals launches generic Erythromycin tablets in U.S.
Most pharma executives see digital drug delivery as important, Molex says
A survey conducted by Molex and its Phillips-Medisize medical device delivery division highlights the importance of digitized drug delivery. Lisle, Ill.-based Molex and Phillips-Medisize commissioned Dimensional Research to poll 215 pharmaceutical … [Read More...] about Most pharma executives see digital drug delivery as important, Molex says
Smiths Medical partners with Ivenix on infusion management suite
Smiths Medical announced today that it partnered with Ivenix on infusion management. Minneapolis-based Smiths Medical will invest an unspecified amount in the long-term partnership to "revolutionize" infusion management and improve patient safety … [Read More...] about Smiths Medical partners with Ivenix on infusion management suite
In case you missed it
- Gyroscope Therapeutics launches IPO roadshow
- BD’s Alaris pump hit with another serious recall
- FDA approves higher dosage of naloxone nasal spray
- Bexson Biomedical wins U.S. patent for ketamine formulation
- Dexcom dips after hours despite Street-beating Q1, raised guidance
- Vascular Therapies touts surgical stenosis treatment trial despite missed primary endpoint
- West Pharmaceutical Services beats Street in Q1, raises guidance
- Merck comes up short on Q1 forecast
- Teva Pharmaceuticals unchanged before hours on Q1 earnings beat
- Canada approves J&J Vision’s drug-eluting contact lens
- Valeo Pharma closes upsized $6.6M private placement
- Timberlake appointed as Berkshire Biomedical CEO
- FDA grants breakthrough nod for Fractyl’s type 2 diabetes treatment
- BD applies to start shipping Alaris pumps again
- Glytec raises $21M for insulin dosing management tech
Clinical Trials
Oncopeptides completes enrollment in Phase 2 multiple myeloma study
Oncopeptides announced today that it completed patient enrollment for its Phase 2 Port study of its multiple myeloma treatment. Waltham, Mass.-based Oncopeptides’ Port study is an open-label, randomized, crossover study comparing the safety, tolerability and efficacy of peripheral or central intravenous administration of Pepaxto (melphalan flufenamide) in combination with dexamethasone to treat relapsed refractory multiple […]
Vascular Therapies touts surgical stenosis treatment trial despite missed primary endpoint
Vascular Therapies announced today that a Phase 3 clinical trial of its Sirogen sirolimus formulation showed encouraging outcomes. Cresskill, N.J.-based Vascular Therapies designed its Sirogen proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. The Phase 3 clinical trial evaluated Sirogen in elderly end-stage renal disease patients, according to […]
FDA grants breakthrough nod for Fractyl’s type 2 diabetes treatment
Fractyl Laboratories announced today that it received FDA breakthrough device designation for its Revita DMR type 2 diabetes treatment. Lexington, Mass.-based Fractyl’s Revita DMR treatment is an outpatient endoscopic procedure designed to resurface the upper intestine lining (duodenal mucosa) in metabolic disease for patients with insulin-treated type 2 diabetes. Preliminary clinical findings suggest that the […]
Delpor doses first patient in once-yearly risperidone implant trial
Delpor announced today that it dosed the first patient in a Phase 1b/2a clinical trial for its DLP-114 risperidone implant. DLP-114 is a long-acting formulation of the antipsychotic risperidone for schizophrenia maintenance therapy. The open-label study is to evaluate the safety, tolerability and pharmacokinetics of switching from oral risperidone to the once- or twice-yearly DLP-114 […]
Cure Pharmaceutical touts data from Curefilm Blue trial for erectile dysfunction
Cure Pharmaceutical announced today that it observed positive results from a trial for its Curefilm Blue platform. Oxnard, Calif.-based Cure touted the results of its initial pharmacokinetics (PK)/bioequivalence studies ahead of the advancement of its clinical program in pursuit of FDA approval, according to a news release. The company did not reveal the specific data, […]
